A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

An Open-label Study of Avastin in Combination With Chemotherapy Regimens as Second-line Treatment in Patients With Metastatic Colon or Rectal Cancer

This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum. The anticipated time of study treatment is until disease progression.

Inclusion Criteria:

• Patients with metastatic colon or rectal cancer, progressing or relapsing after first-line treatment;
• Women of childbearing potential must use adequate contraception up to at least 6 months after the last dose of bevacizumab.

Exclusion Criteria:

• Patients with metastatic colon or rectal cancer scheduled for a first-line systemic treatment;
• Untreated brain metastases, spinal cord compression or primary brain tumours;
• Pregnant or lactating women;
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study start;
• Treatment with any investigational drug, or participation in another investigational study, within 30 days prior to enrollment.